Krystal Biotech Inc (KRYS)
182.29
+4.19
(+2.35%)
USD |
NASDAQ |
Nov 21, 16:00
182.47
+0.18
(+0.10%)
After-Hours: 20:00
Krystal Biotech Enterprise Value: 4.654B for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 4.654B |
| November 20, 2024 | 4.534B |
| November 19, 2024 | 4.527B |
| November 18, 2024 | 4.463B |
| November 15, 2024 | 4.322B |
| November 14, 2024 | 4.514B |
| November 13, 2024 | 4.710B |
| November 12, 2024 | 4.796B |
| November 11, 2024 | 5.045B |
| November 08, 2024 | 5.153B |
| November 07, 2024 | 4.745B |
| November 06, 2024 | 4.677B |
| November 05, 2024 | 4.428B |
| November 04, 2024 | 4.325B |
| November 01, 2024 | 4.485B |
| October 31, 2024 | 4.374B |
| October 30, 2024 | 4.460B |
| October 29, 2024 | 4.480B |
| October 28, 2024 | 4.499B |
| October 25, 2024 | 4.459B |
| October 24, 2024 | 4.443B |
| October 23, 2024 | 4.379B |
| October 22, 2024 | 4.450B |
| October 21, 2024 | 4.559B |
| October 18, 2024 | 4.565B |
| Date | Value |
|---|---|
| October 17, 2024 | 4.496B |
| October 16, 2024 | 4.524B |
| October 15, 2024 | 4.544B |
| October 14, 2024 | 4.576B |
| October 11, 2024 | 4.551B |
| October 10, 2024 | 4.391B |
| October 09, 2024 | 4.357B |
| October 08, 2024 | 4.440B |
| October 07, 2024 | 4.444B |
| October 04, 2024 | 4.505B |
| October 03, 2024 | 4.471B |
| October 02, 2024 | 4.513B |
| October 01, 2024 | 4.630B |
| September 30, 2024 | 4.646B |
| September 27, 2024 | 4.530B |
| September 26, 2024 | 4.566B |
| September 25, 2024 | 4.598B |
| September 24, 2024 | 4.597B |
| September 23, 2024 | 4.617B |
| September 20, 2024 | 4.732B |
| September 19, 2024 | 4.740B |
| September 18, 2024 | 4.691B |
| September 17, 2024 | 4.878B |
| September 16, 2024 | 5.022B |
| September 13, 2024 | 5.232B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
414.19M
Minimum
Mar 18 2020
5.574B
Maximum
Jul 26 2024
1.879B
Average
1.377B
Median
Enterprise Value Benchmarks
| Bioventus Inc | 1.131B |
| ADMA Biologics Inc | 5.050B |
| Alnylam Pharmaceuticals Inc | 30.08B |
| Amicus Therapeutics Inc | 2.978B |
| Rhythm Pharmaceuticals Inc | 3.329B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 27.18M |
| Revenue (Quarterly) | 83.84M |
| Total Expenses (Quarterly) | 48.91M |
| EPS Diluted (Quarterly) | 0.91 |
| Gross Profit Margin (Quarterly) | 92.03% |
| Profit Margin (Quarterly) | 32.42% |
| Earnings Yield | 0.98% |
| Operating Earnings Yield | 1.21% |
| Normalized Earnings Yield | 1.595 |